A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza.

Influenza Clinical Trial

Official title:

A Phase III, Multicenter, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza.

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01224795
• Other study ID #: BCX1812-304
• Secondary ID: HHS 010020070003
• Status: Terminated
• Phase: Phase 3
• First received: October 19, 2010
• Last updated: December 15, 2014
• Start date: October 2010
• Est. completion date: November 2010

Study information

• Verified date: December 2014
• Source: BioCryst Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationCanada: Health Canada
• Study type: Interventional

Clinical Trial Summary

This is a study to evaluate the efficacy and safety of a single dose of intravenous peramivir versus placebo in adolescents and adults with acute uncomplicated influenza.

Description:

This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a single dose of intravenous peramivir versus placebo in adolescents and adults with acute,uncomplicated influenza.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 1
• Est. completion date: November 2010
• Est. primary completion date: November 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 12 Years and older

Eligibility

Inclusion Criteria:

• Male and non-pregnant female subjects age =12 years.

• Test positive for influenza A or B by Rapid Antigen Test (RAT) performed with a commercially available test on an adequate anterior nasal specimen in accordance with the manufacturer's instructions.

• Presence of at least one respiratory symptom (cough, sore throat, or nasal symptoms) of at least moderate severity.

• Presence of at least one constitutional symptom (myalgia [aches and pains], headache,feverishness, or fatigue) of at least moderate severity.

• Onset of symptoms no more than 36 hours before presentation for screening.

• Written informed consent/assent.

Exclusion Criteria:

• Women who are pregnant or breast-feeding.

• Employees of the study site, or immediate family members of study site employees.

• Presence of clinically significant signs of acute respiratory distress.

• History of severe chronic obstructive pulmonary disease (COPD) or severe persistent asthma.

• History of heart failure or angina requiring daily pharmacotherapy with symptoms consistent with New York Heart Association Class III or IV functional status within the past 12 months.

• History of chronic renal impairment requiring hemodialysis and/or known or suspected to have moderate or severe renal impairment (actual or estimated creatinine clearance <50 mL/min).

• Clinical evidence of worsening of any chronic medical condition (temporally associated with the onset of symptoms of influenza) which, in the investigator's opinion, indicates that such finding(s) could represent complications of influenza.

• Current clinical evidence, including clinical signs and/or symptoms consistent with otitis media,bronchitis, sinusitis and/or pneumonia, or active bacterial infection of any body site that requires therapy with oral or systemic antibiotics.

• Presence of immunocompromised status due to chronic illness, previous organ transplant, or use of immunosuppressive medical therapy which would include oral or systemic treatment with > 10 mg ic treatment with > 10 mg prednisone or equivalent on a daily basis within 30 days of screening.

• Presence of known HIV infection with a CD4 count <350 cell/mm3.

• Receipt of any dose of rimantadine, amantadine, zanamivir, or oseltamivir in the 7 days prior to screening.

• Immunization against influenza with live attenuated virus vaccine (FluMist®) in the previous 21 days.

• History of alcohol abuse or drug addiction within 1 year prior to admission in the study.

• Participation in a previous study of intramuscular or intravenous peramivir, or previous exposure to peramivir.

• Participation in a study of any investigational drug or device within the last 30 days.

• Presence of any pre-existing illness that, in the opinion of the investigator, would place the subject at an unreasonably increased risk through participation in this study.

• Presence of any pre-existing illness that in the opinion of the investigator would make the subject unable to comply with the protocol.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Influenza
• Influenza, Human

Intervention

Drug:
• Peramivir
Adults (= 18 years): Peramivir 600 mg, administered intravenously. Adolescents (12 to < 18 years): Peramivir 10 mg/kg (not to exceed a maximum dose of 600 mg), administered intravenously.
• Placebo Comparator
Placebo Peramivir, administered intravenously.

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
BioCryst Pharmaceuticals	Department of Health and Human Services

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To evaluate the efficacy of peramivir administered intravenously compared to placebo on the time to alleviation of clinical symptoms with acute uncomplicated influenza.	Time to alleviation of clinical symptoms in adolescents and adults with uncomplicated acute influenza measured from patient reported study diaries.	14 Days	No
Secondary	To evaluate the safety and tolerability of peramivir administered intravenously	To evaluate time to resolution of fever in response to treatment. To evaluate changes in influenza virus titer in nasal and pharyngeal samples (viral shedding) in response to treatment.; To evaluate secondary clinical outcomes and changes in virus susceptibility to neuraminidase inhibitors in response to treatment.	14 Days	No